Journal
SEMINARS IN IMMUNOLOGY
Volume 22, Issue 3, Pages 105-112Publisher
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.smim.2010.02.001
Keywords
Cancer; Vaccine(s); Immunotherapy; Immunosurveillance
Categories
Funding
- Alliance for Cancer Gene Therapy, Inc. [5P01CA109094]
- NATIONAL CANCER INSTITUTE [P01CA109094] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Despite enormous effort, promising pre-clinical data in animal studies and over 900 clinical trials in the United States, no cancer vaccine has ever been approved for clinical use. Over the past decade a great deal of progress has been in both laboratory and clinical studies defining the interactions between developing tumors and the immune system. The results of these studies provide a rationale that may help explain the failure of recent therapeutic cancer vaccines in terms of vaccine principles, in selecting which tumors are the most appropriate to target and instruct the design and implementation of state-of-the-art cancer vaccines. (C) 2010 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available